AstraZeneca, along with its biologics research and development arm MedImmune, has secured approval from the Japanese ministry of health, labour and welfare for Imfinzi (durvalumab) as maintenance therapy
CVC Fund VII has agreed to acquire holding company, FIMEI, which owns a 51% stake in Recordati. The consortium is comprised of PSP Investments and StepStone. FIMEI chairman and
The chemotherapy used in combination with Tecentriq is Abraxane [albumin-bound paclitaxel; nab-paclitaxel]). The late-stage trial dubbed IMpassion130 was found to have reduced the risk of disease worsening or
The approval is for patients with unresectable or metastatic melanoma and who are positive to BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. Array BioPharma said the
The study assessed Ibrance in combination with fulvestrant against placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
The CHMP’s opinion is for the approval of the drug’s marketing authorisation application (MAA) for the extended adjuvant treatment of early stage HER2-positive hormone receptor positive breast cancer.
Zemdri, which is an intravenous infusion and administered once daily, was approved to treat adults with cUTI, including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or
The two forms of epilepsy that are covered by the approval are Lennox-Gastaut syndrome and Dravet syndrome in patients, aged two years or more. Epidiolex is now the
SNG001 was shown to be well tolerated in the two-part mid-stage trial, dubbed SG015, as per the interim safety data, said the UK-based respiratory drug discovery and development
The new facility will help the company to incorporate biologicals analytical and process development, as well as manufacturing units into one unit, enabling to maximize synergies and increase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.